![](https://investorshub.advfn.com/uicon/430424.png?cb=1554906782)
Monday, April 18, 2016 4:42:49 PM
The answer in the UCLA paper is that TIL count in SOC patients' tumors did not make a difference in survival.
I found UCLA to be confirmed in a 2013 paper in Clinical Cancer Research.
TILs are not associated with prolonged with survival (171 patient cases reviewed)
TILs were not associated with prolonged survival in univariate analyses. We compared the survival of cases with absent (0) lymphocytes, present (1+) and abundant (2+) lymphocytes using a log-rank test (p>0.05) (Figure 3). We found patient age was a highly significant predictor of survival (p<0.001); however, lymphocytes did not vary according to age. The mean age of patients with absent (0), present (1+) and abundant (2+) lymphocytes was 56.9 (SD ± 14.6), 57.3 (SD ± 12.1) and 54.8 years (SD ± 13.1), respectively (p>0.05). TILs were not a significant predictor of survival in an age-adjusted Cox proportional hazards model (data not shown) (p>0.05). If tumors belonging to the classical transcriptional class were excluded, there were no survival differences according to TILs among proneural, neural and mesenchymal tumors (p>0.05). Similarly, if mesenchymal tumors were excluded, there were no survival differences according to TILs among proneural, neural and classical tumors (p>0.05). www.ncbi.nlm.nih.gov/pmc/articles/PMC3865611/
In other words, I think the UCLA paper and this paper together demonstrate TIL count does not make a difference in GBM when treated with SOC.
I don't know if many people know this, because SOC can make a difference in other types of cancers to one degree or another that have high TIL counts.
While this does not remove all questions, I think it helps confirm.
Respect Risk. Conduct Your Own Due Diligence. Manage your assets wisely. Diversify.
Recent NWBO News
- Biophma Announces Exclusive In License for Dendritic Cell Technology, Sending Shares Higher • AllPennyStocks.com • 06/17/2024 04:40:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/04/2024 09:11:16 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 06/03/2024 09:22:55 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 05/22/2024 08:13:36 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/10/2024 09:04:57 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 03/01/2024 10:04:38 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/02/2023 01:31:35 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/16/2023 10:11:54 PM
- Epazz, Inc. (OTC Pink: EPAZ) ZenaDrone Demonstration to Defense Departments of UAE and Saudi Arabia • InvestorsHub NewsWire • 11/15/2023 12:19:31 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/09/2023 09:30:39 PM
- Epazz, Inc. (OTC Pink: EPAZ) US Navy Collaboration ZenaDrone 1000 • InvestorsHub NewsWire • 11/09/2023 01:00:34 PM
- Epazz, Inc. (OTC Pink: EPAZ) US Navy Collaboration ZenaDrone 1000 Extreme Weather Demo • InvestorsHub NewsWire • 11/07/2023 12:29:43 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/09/2023 08:36:14 PM
North Bay Resources Announces Composite Assays of 0.53 and 0.44 Troy Ounces per Ton Gold in Trenches B + C at Fran Gold, British Columbia • NBRI • Jun 18, 2024 9:18 AM
VAYK Assembling New Management Team for $64 Billion Domestic Market • VAYK • Jun 18, 2024 9:00 AM
Fifty 1 Labs, Inc Announces Acquisition of Drago Knives, LLC • CAFI • Jun 18, 2024 8:45 AM
Hydromer Announces Attainment of ISO 13485 Certification • HYDI • Jun 17, 2024 9:22 AM
ECGI Holdings Announces LOI to Acquire Pacific Saddlery to Capitalize on $12.72 Billion Market Potential • ECGI • Jun 13, 2024 9:50 AM
Fifty 1 Labs, Inc. Announces Major Strategic Advancements and Shareholder Updates • CAFI • Jun 13, 2024 8:45 AM